M
Michael L. Steinberg
Researcher at University of California, Los Angeles
Publications - 297
Citations - 6538
Michael L. Steinberg is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Radiation therapy & Prostate cancer. The author has an hindex of 30, co-authored 253 publications receiving 5024 citations. Previous affiliations of Michael L. Steinberg include American Society for Radiation Oncology & University of Birmingham.
Papers
More filters
Journal ArticleDOI
Delivering affordable cancer care in high-income countries
Richard Sullivan,Jeffrey Peppercorn,Karol Sikora,John Zalcberg,Neal J. Meropol,Eitan Amir,David Khayat,Peter Boyle,Philippe Autier,Ian F. Tannock,Tito Fojo,Jim Siderov,Steve Williamson,Silvia Camporesi,J. Gordon McVie,Arnie Purushotham,Peter Naredi,Alexander M.M. Eggermont,Murray F. Brennan,Michael L. Steinberg,Mark De Ridder,Susan A. McCloskey,Dirk Verellen,Terence Roberts,Guy Storme,Rodney J. Hicks,Peter J. Ell,Bradford R. Hirsch,David P. Carbone,Kevin A. Schulman,Paul Catchpole,David Taylor,Jan Geissler,Nancy G Brinker,David O. Meltzer,David J. Kerr,Matti Aapro +36 more
TL;DR: Urgent solutions range from re-engineering of the macroeconomic basis of cancer costs (eg, value-based approaches to bend the cost curve and allow cost-saving technologies), greater education of policy makers, and an informed and transparent regulatory system.
Journal ArticleDOI
American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy.
Louis Potters,Brian D. Kavanagh,James M. Galvin,James M. Hevezi,Nora A. Janjan,David A. Larson,Minesh P. Mehta,Samuel Ryu,Michael L. Steinberg,Robert Timmerman,James S. Welsh,Seth A. Rosenthal +11 more
TL;DR: These guidelines are an educational tool designed to assist practitioners in providing appropriate radiologic care for patients and are not intended, nor should they be used, to establish a legal standard of care.
Journal ArticleDOI
Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials
Christopher R. King,Debra Freeman,Irving D. Kaplan,Donald B. Fuller,Giampaolo Bolzicco,Sean P. Collins,Robert J. Meier,Jason Wang,Patrick A. Kupelian,Michael L. Steinberg,Alan W. Katz +10 more
TL;DR: PSA relapse-free survival rates after SBRT compare favorably with other definitive treatments for low and intermediate risk patients, and the current evidence supports consideration of S BRT among the therapeutic options for these patients.
Journal ArticleDOI
Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study
Allen M. Chen,Carol Felix,Pin-Chieh Wang,R.N. Sophia Hsu,Vincent Basehart,Jordan H. Garst,P.J. Beron,Deborah Wong,Michael H. Rosove,Shyam Rao,Heather Melanson,Edward J. Kim,Daphne Palmer,Lihong Qi,Karen Kelly,Michael L. Steinberg,Patrick A. Kupelian,Megan E. Daly +17 more
TL;DR: Chemoradiotherapy with radiation doses reduced by 15-20% was associated with high progression-free survival and an improved toxicity profile compared with historical regimens using standard doses.
Journal ArticleDOI
Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.
Amar U. Kishan,Ryan Cook,Jay P. Ciezki,Ashley E. Ross,Mark Pomerantz,Paul L. Nguyen,Talha Shaikh,Phuoc T. Tran,Kiri A. Sandler,Richard G. Stock,Gregory S. Merrick,D. Jeffrey Demanes,Daniel E. Spratt,Eyad Abu-Isa,Trude B. Wedde,Wolfgang Lilleby,Daniel J. Krauss,Grace Shaw,Ridwan Alam,Chandana A. Reddy,Andrew J. Stephenson,Eric A. Klein,Danny Y. Song,Jeffrey J. Tosoian,John V. Hegde,Sun Mi Yoo,Ryan Fiano,Anthony V. D'Amico,Nicholas G. Nickols,Nicholas G. Nickols,William J. Aronson,Ahmad Sadeghi,Stephen Greco,Curtiland Deville,Todd McNutt,Theodore L. DeWeese,Robert E. Reiter,J. Said,Michael L. Steinberg,Eric M. Horwitz,Patrick A. Kupelian,Patrick A. Kupelian,Christopher R. King +42 more
TL;DR: Among patients with Gleason score 9-10 prostate cancer, treatment with EBRT+BT with androgen deprivation therapy was associated with significantly better prostate cancer–specific mortality and longer time to distant metastasis.